



MOLECULAR INSIGHTS AND GENETIC IMPLICATIONS IN PARKINSONISM-DEMENTIA-AMYOTROPHIC LATERAL SCLEROSIS COMPLEX: A CASE REPORT

Dr. Rehana Masood¹, Rabi Taj², Tanzeela Noreen Alvi³, Dr. Sadia Javeed⁴, Likowsky Desir⁵,
Maher Ali Rusho⁶, Tariq Rafique^{7*}, Zohaib Tariq⁸

¹Assistant professor, Department of Biochemistry, Shaheed Benazir Bhutto Women University, Peshawar Pakistan, Sina Labs and Diagnostic Centre, Hayatabad, Peshawar Pakistan

²Department of Zoology, Shaheed Benazir Bhutto Women University, Charsadda Road, Peshawar, Pakistan

³Research Associate, School of Biological Sciences, University of the Punjab, Pakistan

⁴Women Medical Officer Social Security Hospital (PESSI: Punjab Employees Social Security Institution) Sahiwal, Pakistan

⁵MPH, MSc, Department of Surgery, Wyckoff Heights Medical Center, United States

⁶Department of Lockheed Martin Engineering Management, University of Colorado, Boulder, Boulder, CO 80309, USA

^{7*}Assistant Professor Dadabhoy Institute of Higher Education, Karachi, Pakistan

⁸MS Scholar, Department of Physics, University of Lahore, Sargodha Campus, Sargodha, Pakistan

***Corresponding Author:** Tariq Rafique

*Assistant Professor Dadabhoy Institute of Higher Education, Karachi, Pakistan

Abstract

Introduction: The parkinsonism-dementia-amyotrophic lateral sclerosis complex was first described in the islands of Guam, with its peak incidence in the 1950s. Due to its rarity, we present a clinical case to shed light on this association. The objective is to describe the nosological and pathogenetic implications of this neurodegenerative disease, particularly in populations where this association is unexpected.

Clinical Case: We report a case of Pakistani origin with systemic symptoms evolving over 5 years, followed by cognitive alterations. Subsequently, the patient developed gait disturbances and motor symptoms suggestive of parkinsonism with atypical features and signs of motor neuron disease. Extension studies confirmed the involvement of both upper and lower motor neurons, with a mutation observed in the POLG gene associated with mitochondrial depletion syndrome.

Conclusion: Despite being a known association, diagnosis of this entity remains challenging clinically. Molecular mechanisms have not been fully elucidated; common genes associated with parkinsonism and amyotrophic lateral sclerosis have been ruled out, with attempts to localize the locus yielding inconclusive results. Unfortunately, the prognosis remains fatal, and there are currently no disease-modifying treatments available.

Keywords: Parkinsonism, Dementia, Amyotrophic Lateral Sclerosis, Neurodegenerative Disease

INTRODUCTION:

Parkinson's disease is the best-characterized hypokinetic movement disorder. It is essential to differentiate it from atypical parkinsonism, which is a clinical form with a more progressive and degenerative course. Similarly, amyotrophic lateral sclerosis (ALS) is a motor neuron disease that can be accompanied by parkinsonism in 5-17%. The association between the two diseases is well documented and was first described in the islands of Guam, where it was found; it is known as Lytico-Bodig disease (Candeias et al., 2024).

This is consistent with its translation into the Guajan or Chamorro language: lytic due to paralysis attributable to ALS, bodega attributable to "laziness" within the Parkinsonian spectrum. This pathology had its peak incidence in the 1950s. We currently find most cases reported in Guam, New Guinea and Japan; outside this area, we found few reported cases. His age at presentation ranges from 54 to 74 years. The disease remains degenerative and fatal without disease-modifying treatments (Young et al., 2024).

CLINICAL CASE:

A 73-year-old man of Latin American origin with a history of a mother diagnosed with Alzheimer's dementia with a negative genetic panel, a brother diagnosed with ALS, and a sister diagnosed with Parkinson's disease. Progressive symptoms began in 2016 and were characterized by progressive symptoms of hyposmia, hearing loss, constipation, and insomnia, which warranted evaluation by an otolaryngologist and an audiologist without a diagnostic conclusion. In 2020, family members noticed that the patient had problems with episodic memory, forgetting objects of daily life, and problems with profit in business (trade) (Bartók & Csanády, 2024).

These symptoms were progressive until the patient began to have limitations in daily activities, such as driving, changing speeds, and leaving home. At the end of that year, the patient began to present distal muscle weakness, manifested when opening bottles and brushing his teeth, which progressed in an insidious, non-fluctuating manner without a predominance of schedules (Sofyantoro et al., 2024).

In January 2021, the patient began to have gait disorders, which led her to frequent falls, up to more than 6 times a week, due to postural instability. The patient came for evaluation in May. A 16-point MoCA test was performed with alterations in speech fluency and sentence repetition in abstraction, deferred memory and visuospatial and dysexecutive problems. Luria's test came back positive. The patient presented with a hypomimic facial expression, hypophonic, discontinuous and slow speech and a decreased gag reflex, generalized rigidity predominantly on the left, generalized hypotrophy, bradykinesia predominantly on the left, generalized strength 4/5, muscle stretch reflexes 3/ 4, abdominocutaneous reflexes abolished, Hoffmann and Trömner signs present bilaterally, bilateral extensor plantar response, lower extremity fasciculations evoked by jumping, gait with short steps, freezing of gait when turning, positive traction test (postural instability). Managed with levodopacarbido for a gradual dose. At follow-up after 3 months, the patient With these results, magnetic resonance imaging (MRI) of the brain was performed (Figure 1) (Bhatt et al., 2024).




Figure 1 Digital T1-weighted and Axial-weighted FLAIR Magnetic Resonance Imaging

A: A decrease in volume is observed at the mesencephalic level, with the volume of the pons preserved, and at the cortical level, there is an increase in the diameter of the sulci and fissures. B: mesencephalic atrophy is seen, concavity in the mesencephalic tegmentum (blue arrow)

Neuroconduction velocity (NCV) showed thoracic limb motor axonal neuropathy related to atrophy and sensory neuroconduction without alterations. Electromyography (EMG) showed data of active denervation (increased insertion activity, fibrillation potentials, fasciculation) and chronic reinnervation (polyphasic motor unit action). potentials and low recruitment at maximum contraction) in the 5 body segments, which is compatible with motor neuron disease (figures 2, 3 and 4) (Goswami & Carra, 2024).

EMG showed increased insertion activity in the bilateral deltoid, biceps, triceps, common digital extensors, and bilateral lingual muscles. Abundant fibrillation potential was observed, and fasciculation predominated in the thoracic limb muscles. Polyphasic, high-amplitude activation of the motor unit action potential (PAUM) was observed during contraction. At maximal contraction, decreased recruitment was observed in most muscles evaluated (Hartopp, Markovinovic, Miller, & Gomez-Suaga, 2024).

Figure 2 Sensory neuroconduction velocity

Nerve	Stimulation site	Recording site	Day 5						Day 12							
			Distal latency (ms)		Amplitude (mV or μ V)		Conduction velocity (m/s)		Distal latency (ms)		Amplitude (mV or μ V)		Conduction velocity (m/s)			
			RT	LT	RT	LT	RT	LT	RT	LT	RT	LT	RT	LT		
Median (M)	Wrist	APB	3.2	4.1 [†]	6.0	4.5 ^{**}	5.5	2.4 ^{**}	48.5 [†]	48.0 [†]	3.4	3.9	2.0 [†]	2.3 [†]		
	Elbow														54.3	49.2
Ulnar (M)	Wrist	ADM	2.7	2.6	3.2 ^{**}	3.5 [†]	1.7 ^{**}	3.2 [†]	58.4	56.5	2.7	2.9	0.3 [†]	1.2 [†]	58.7	55.0
	BE														60.0	50.5
Peroneal (M)	Ankle	EDB	4.7	4.3	7.5	8.1	0.5 [†]	1.7 [†]	53.3	43.6 [†]	3.9	3.6	2.5 [†]	2.1 [†]		
	Fibula head														45.2	44.5
Tibial (M)	PF	AH			3.6	6.7	21.9	20.7	42.7	39.2	3.3	3.5	2.1 [†]	2.0 [†]	50.5	48.0
	Ankle														43.5	43.9
Median (S)	Digit II	Wrist	2.8	3.0	18.5	12.8	44.0	48.4	34.0 [†]	37.3 [†]	2.6	2.9	1.9 [†]	2.4 [†]	44.9	41.8
	Wrist	Elbow	3.6	3.6	45.2	45.1	40.9	50.7	50.7	3.6	3.6	51.1	46.1	52.1	51.5	
Ulnar (S)	Digit V	Wrist	2.4	2.6	17.6	22.4	2.4	2.6	40.9	39.2	2.4	2.8	18.8	11.4	42.9	39.1
	Wrist	BE	3.3	3.5	63.9	70.9	3.2	3.2	54.0	51.6	3.2	3.2	47.6	78.1	57.3	54.2
Sural (S)	BE	AE	4.8	4.8	18.1	14.1	22.7	16.1	58.4	58.4	4.7	4.8	22.7	16.1	60.2	57.4
	Lateral malleolus	Lateral calf	3.7	3.8	38.7	22.2	32.5	31.6	2.7	3.1	23.1	19.5	45.2	39.1		

Study of normal sensory neuroconduction in all 4 extremities

Figure 3 Speed from motor neuroconduction

	n = 154			n = 62		n = 92
Median	Total*	15th perc**	75th perc**	Men	Women	
Latency	3.2 ± 1	2.8	3.4	3.2 ± 0.9	3.2 ± 1	
Amplitude	9.7 ± 6.6	6.5	11.8	9.4 ± 6.4	9.8 ± 6.8	
Velocity	59 ± 8.2	54	62	59 ± 8.6	58.7 ± 8	
Ulnar	Total	15th perc	75th perc	Men	Women	
Latency	3 ± 0.6	2.7	3.2	3 ± 0.6	2.9 ± 0.6	
Amplitude	9.2 ± 4.6	6.8	10.9	9.2 ± 4.4	9.2 ± 4.6	
Velocity	63.6 ± 14.6	56	68	62 ± 10.8	64 ± 16.4	
Tibial	Total	15th perc	75th perc	Men	Women	
Latency	3.4 ± 1	3	3.6	3.5 ± 1.2	3.3 ± 0.8	
Amplitude	14 ± 9	9.2	17	13 ± 7.2	15 ± 10	
Velocity	49 ± 7.6	45	51	49 ± 8.4	48.8 ± 7	
Peroneal	Total	15th perc	75th perc	Men	Women	
Latency	3.4 ± 1.4	2.8	3.7	3.6 ± 1.4	3.3 ± 1.4	
Amplitude	7.36 ± 5.8	4.2	9.4	7.5 ± 6	7.3 ± 5.6	
Velocity	51 ± 9	47	54	51.6 ± 9.2	51 ± 8.6	

Motor neuroconduction with moderately reduced amplitudes in the thoracic extremities, compatible with the axonal pattern

EMG showed increased insertion activity in the bilateral deltoid, biceps, triceps, common digital extensors, and bilateral lingual muscles. Abundant fibrillation potential was observed, and fasciculation predominated in the thoracic limb muscles. Polyphasic, high-amplitude activation of the motor unit action potential (PAUM) was observed during contraction. At maximal contraction, decreased recruitment was observed in most muscles evaluated (Yu et al., 2024).

EMG Summary Table		Spontaneous					MUAP				
Muscle	Nerve	Roots	IA	Fib	PSW	Fasc	Recruit	Effort	Dur.	Amp	PPP
R. Deltoid	Axillary	C5-C6	Increased	2+	3+	None	Reduced	N	N	Mod Incr	Rare
R. Biceps brachii	Musculocutaneous	C5-C6	Increased	2+	2+	Many	Reduced	N	Mod Incr	Mod Incr	N
R. Abductor pollicis brevis	Median	C8-T1	Increased	2+	3+	Rare	1MUP	N	N	Gr Incr	N
R. Tibialis anterior	Deep peroneal (Fibular)	L4-L5	Increased	1+	3+	Few	N	N	N	N	Few
R. Gastrocnemius (Medial head)	Tibial	S1-S2	Increased	1+	1+	Rare	N	N	N	N	N
R. Vastus medialis	Femoral	L2-L4	N	None	None	Rare	N	N	N	N	N
R. Vastus lateralis	Femoral	L2-L4	N	None	None	None	N	N	N	N	N
R. T10 paraspinal	Spinal	T10-	Increased	None	1+	Rare	N	N	N	N	N
L. Deltoid	Axillary	C5-C6	Increased	2+	2+	Rare	Reduced	N	SI Incr	N	N
L. First dorsal interosseous	Ulnar	C8-T1	Increased	2+	2+	Rare	Reduced	N	SI Incr	Mod Incr	N

Figure 4 Electromyography of the 4 extremities, axial segment and bulbar region

DISCUSSION:

The patient was lost to follow-up for one year. Upon returning for evaluation, he was bedridden and aphasic, with increasing signs of parkinsonism and motor neuron syndrome. It was decided to perform a negative genetic panel for C9ORF72 and 143 other genes involved in neuromuscular and neurodegenerative diseases, including the VCP genes. MAT3, associated with ALS, NOTCH3, associated with frontotemporal dementia, without alterations. A pathogenic variant finding has been reported for the POLG gene: C.2209G>C, p.(Gly737Arg), related to autosomal dominant and recessive mitochondrial depletion syndrome. A genetic counselling session was held, and the patient was informed. In May 2022, the patient presented with dysphagia and, arrived in a wheelchair and was then sent to undergo gastrostomy. The table shows a series of reported cases of association between parkinsonism-dementia and ALS (Baskerville, Rapuri, Mehlhop, & Coyne, 2024; Morrow, 2024).

Parkinsonism-dementia association and ALS are degenerative diseases of the central nervous system (CNS) that share similar pathophysiological mechanisms and can develop in the same patient. The relationship between these disorders was first observed in Guam. In this location, it was 100 times higher than in any other population, and many of these patients had an association with the parkinsonism-dementia complex (Wang, Liu, Ren, Guo, & Wang, 2024).

Extrapyramidal signs and symptoms have been found in ALS due to dysfunction nigrostriatal. 5-HT_{1A}-Hydroxytryptamine, also called serotonin, produced in the raphe nucleus, is involved in the regulation of physiological events such as motor control, the sleep-wake cycle, nociception, cardiorespiratory functions, body temperature, consciousness, learning and memory (Y. Wang et al., 2024).

Serotonin receptors 5-HT_{1A/1B} and 5-HT_{2A-C} are crucial in ALS and atypical parkinsonism. The first is located in the hippocampus, amygdala, hypothalamus, and basal ganglia. The 5-HT_{1B} receptor is found primarily in axonal terminals of the basal ganglia and substantia nigra, as well as in presynaptic GABA terminals and the thalamostriate and corticostriate, glutaminergic neurons. In Parkinson's disease, loss of up to 56% of serotonergic neurons occurs, especially in the basal ganglia, hypothalamus, hippocampus and prefrontal cortex (Aubrey et al., 2024; da Silva, Cardoso, & Sales, 2024).

After 70 years, the etiology remains unclear. There are many hypotheses, including cycad toxin and toxic beta-methylamino-L-alanine. Pathologically, it is a multiple proteinopathy composed of Au, alpha-synuclein and TDP-43. These findings imply that one or more triggers may induce this disease in patients with genetic predisposition (Alshaikh, Paul, Moukheiber, Scholz, & Pantelyat, 2024).

Our patient's initial symptoms were the apparent prodromal symptoms of Parkinson's disease and subsequently, cognitive impairment; however, due to the lack of histopathological studies, it is difficult to clarify whether the cognitive alterations were due to the Parkinsonism-dementia complex and ALS or part of the ALS association with frontotemporal dementia. In the first case, the association manifests itself. Approximately 5% of cases present overlapping neuropathological findings, with neurofibrillary tangles containing proteins in the spinal cord and brain. Although the association between ALS and familial frontotemporal dementia, related to the MAPT gene or without mutations, is currently recognized as closer. Our patient had a hereditary family history of Alzheimer's dementia; However, clinical and genetic phenotypes today vary significantly from those of 15 years ago (Mahin et al., 2024).

AUTHOR(S) AND YEAR	COUNTRY	POPULATION	AGE	RESULTS
Hiranodal 1961	Guam Islands	47 cases of parkinsonism, cognitive impairment and ALS.	32-66 years Average: fifth and sixth decades of life.	Death occurs within an interval of 3 to 5 years; 7% of deaths among Guam's adult population. Clinical features: dementia, parkinsonian syndrome and motor neuron involvement.
Kimurattal 1982	NewWestern Guinea	97 cases of ALS, 19 cases of Parkinson's disease and 18 of poliomyeloradiculitis.	The mean ages at the start are 33, 43, and 26 years.	Evaluated population of 7000 inhabitants, of which 134 were affected with the disease described. No manufactured products (including metals, ceramics, textiles, petrochemicals, paints, dyes or solvents) were available to them.
Garudottal 1985	Guamy IslandsNewWestern Guinea	Population of Guam Islands of New Guinea, about 3200	people were evaluated.	From the fourth to the seventh decade of life. Decrease in the incidence of patients with parkinsonism, dementia and ALS born after 1920.
Bokumiya et al., T2001A2012	Papua, Indonesia	46 cases of ALS or parkinsonism within a population range of 7000 (2001-2002) to 13,900 (2007-2012).	Median fifth to sixth decade of life.	46 cases consisted of 17 definite, probable cases of ALS 3 w, with dementia, 13 overlapping cases of ALS and parkinsonism 5 w, with dementia, 16 cases of parkinsonism, and one with added dementia. Notable decrease compared to 30-35 years ago.
Mannone, 2001	Italy, Palermo	2 cases of ALS with Parkinson's disease.	Man 55 and woman 69 years old.	2 patients who developed Parkinson's disease and ALS. During its evolution, superposition was a distinct nosological entity.

Table no.1 Series of reported cases of parkinsonism-dementia association and ALS in the world

As for ALS, it has a prevalence of between 4 and 5 per 100,000 people, with a higher concentration on the island of Guam and the Kii Peninsula in Japan. The most characteristic from a clinical point of view is progressive motor impairment, which limits the bulbar and respiratory muscles. Some patients also experience changes in emotional expression or cognitive abnormalities. The diagnostic criteria currently used are those of Escoria and Awaji (Martinelli et al., 2024; Xiang et al., 2024).

Based on the diagnostic strength of the clinical evaluation, patients can be classified as definite ALS, probable ALS, or possible ALS. This patient met the criteria for defined ALS based on clinical evidence and electromyography of upper or lower motor neurons in 3 or more regions. Due to the rarity of the Guam complex, no evidence-based diagnostic criteria exist, but consensus exists. A patient must meet the criteria for ALS, parkinsonism, and cognitive impairment, in addition to genetic alterations (Carmona et al., 2024).

Our patient had a poor response to levodopa. An adequate response to levodopa is a supportive criterion for the diagnosis of Parkinson's disease based on the 2015 MDS. Therefore, it reinforces that this case is a form of atypical parkinsonism. The association between patients with Parkinson's disease and patients who have developed ALS, known as Brait-Fahn-Schwartz disease, in which

several standard pathogenetic bases are shared, is well recognized (Iskusnykh, Zakharova, Kryl'skii, & Popova, 2024; Klíčová et al., 2024).

Hereditary spastic plegia, spinocerebellar atrophies, and frontotemporal lobe degeneration are motor neuron disorders with Parkinsonism. However, in ALS, parkinsonian symptoms are present in a range from 5 to 17%, and the most frequent symptoms are postural instability, rigidity and bradykinesia (Gallo et al., 2024).

Neuroimaging And Neurophysiology Studies:

Due to the clinical findings, it is necessary to perform MRI studies of the neuraxis to exclude typical findings of atypical parkinsonisms such as the Hot-Cross-Bun sign, bilateral putaminal hyperintensity, colliculus and midbrain atrophy, frontoparietal asymmetric cortical atrophy, etc. At present, no signs suggestive of the Parkinson-dementia association with ALS can be established by MRI, so the findings are often related to the type of parkinsonism each patient presents. In a study conducted on the Kii Peninsula, mild to severe atrophy of the frontal and temporal lobes was the predominant manifestation (Liu et al., 2024; Manera et al., 2024).

In motor neuron disease, MRI helps us rule out an alternative explanation, such as cervical radiculomyelopathy or some other structural cause, which may explain the lower and upper motor neuron results. Single photon emission computed tomography (CT) can be performed in these patients, highlighting the decrease in cerebral blood flow in the frontal and temporal lobes (Huo et al., 2024).

As a diagnostic complement and having clinical findings of motor neuron disease, it is necessary to perform VCM and EMG studies, which are valuable tools to confirm the absence of sensory involvement and the neurogenic pattern of the disease (Payne et al., 2024).

Differential Diagnosis:

When you have a patient with isolated findings of diffuse weakness, you should consider myopathy, a defect in neuromuscular junction transmission, polyradiculopathy, or predominantly motor polyneuropathy. Myopathy can be excluded due to failure to increase creatine kinase (<1000 U/L) with pre-involvement. The existence of sensory involvement in nerve conduction studies would indicate an inherited acquired polyneuropathy. If the pattern also had demyelinating features, it would suggest chronic inflammatory demyelinating polyradiculoneuropathy or multifocal motor neuropathy, which often constitute differential diagnoses (Tsuji, Nakayama, Taruya, & Ito, 2024; Wu et al., 2024).

Other processes that must be excluded are infectious (varicella-zoster virus, cytomegalovirus, West Nile virus, Lyme disease, HTLV-1/HTLV-2, or HIV) or neoplastic (lymphoma or carcinomatous neoplasm). As regards parkinsonism, generally among the atypical forms that present with dementia, there is supranuclear gaze palsy, which has 7 clinical subtypes. All are accompanied by dementia, in addition to there being a variety that shares symptoms and signs with ALS, corticobasal degeneration, which in this case is accompanied by a behavioural variant of frontotemporal dementia or primary progressive aphasia. Due to the visuospatial alterations, language and positive Luria test, it seems that our patient mainly had a history of dementia (Kwon et al., 2024).

Guam Complex Genetics:

Finally, the Guam complex is believed to share genetic and environmental components (cycads, mineral deficiency, infectious agents, heavy metal toxicity) due to the decreased incidence of disease in these areas and the agricultural changes that have also occurred in the area. However, it is not yet possible to give a shared pathogenetic explanation. Analysis of several genes in this association was reported primarily on the C9ORF72 hexanucleotide repeat expansion in 89 individuals from the Guam/Mariana Islands population with ALS and frontotemporal dementia, and no correlation was found (Jia et al., 2024; Leonard et al., 2024).

Also, expansions and mutations of SOD1 were reported in patients with parkinsonism-dementia and ALS from the Kii Peninsula and in other relatives presenting with ALS, frontotemporal dementia, Parkinson's disease, and ALS-frontotemporal dementia. Mutations in the TDP43 and DJ-1 genes have been identified in multigenerational families of parkinsonism-dementia and ALS. In addition to these association genes, genes associated with atypical parkinsonism and other neuromuscular diseases must be excluded. In the case of our patient, the POLG gene is associated with mitochondrial depletion syndrome. It presents with multiple important clinical phenotypes, such as sensory ataxic neuropathy with gastrointestinal dysmotility and ophthalmoplegia, while slowly progressive dementia and parkinsonism have been found in adults (De Marchi, Venkatesan, Saraceno, Mazzini, & Grossini, 2024),(Jeong et al., 2024).

Although this alteration may be related to clinical manifestations, no cases have been reported. It is recommended to always carry out genetic tests in cases of ALS and complex parkinsonism-dementia due to the high certainty of transmission to other relatives. However, in cases of ALS with associated dementia but without first or second-degree relatives, it is not advisable to perform these tests because the majority of cases are due to sporadic ALS (Neubrand et al., 2024).

The disease continues to have a fatal course, without changing treatments and with respiratory and infectious complications that will lead to death. The prognosis is characterized by a progressive disease, with a survival of 3 to 5 years and, in some cases, up to 10 years of life after the onset of symptoms. In this case, the treatment improves the patient's quality of life. May have, in addition to the control of neuropsychiatric manifestations. It is essential always to remember the use of genetic tests in the Guamy complex and other forms of ALS since the possibility of gene therapy is foreseen in the future (Chen et al., 2024) (Xuan et al., 2024).

CONCLUSION:

The association between parkinsonism-dementia and ALS is an infrequent entity and difficult to diagnose clinically for inexperienced doctors, for whom it represents a diagnostic challenge. Due to the unfavourable prognosis of the disease and the functional limitation it confers, many times, it is not possible to conclude the diagnosis or provide adequate follow-up. The importance of knowing the clinical data of motor neuron disease and the warning of Parkinsonism has made it possible to standardize the diagnostic conduct from the first evaluation.

The patient has a high familial genetic load; his mutation is autosomal dominant and recessive, with a high probability of transmission to another family member. Therefore, the importance of genetic diagnosis is evident. Currently, the association between Guam and the Kiri Islands is highly disputed, so we cannot establish that any relationship exists with this location. We consider the reporting of this case relevant, given that the association between these diseases has drastically decreased since their appearance. Furthermore, reports of overlapping diseases predominate in Mexico, but there are no cases currently reported in the literature from the Guam complex. With this review, we hope to encourage clinicians to adopt a rapid diagnostic approach.

REFERENCES:

1. Alshaikh, J. T., Paul, A., Moukheiber, E., Scholz, S. W., & Pantelyat, A. (2024). VCP mutations and parkinsonism: An emerging link. *Clinical Parkinsonism & Related Disorders*, 10.
2. Aubrey, L. D., Ninkina, N., Ulamec, S. M., Abramycheva, N. Y., Vasili, E., Devine, O. M., . . . Walko, M. (2024). Substitution of Met-38 to Ile in γ -synuclein found in two patients with amyotrophic lateral sclerosis induces aggregation into amyloid. *Proceedings of the National Academy of Sciences*, 121(2), e2309700120.
3. Bartók, Á., & Csanády, L. (2024). TRPM2-an adjustable thermostat. *Cell Calcium*, 102850.
4. Baskerville, V., Rapuri, S., Mehlhop, E., & Coyne, A. N. (2024). SUN1 facilitates CHMP7 nuclear influx and injury cascades in sporadic amyotrophic lateral sclerosis. *Brain*, 147(1), 109-121.

5. Bhatt, N., Puangmalai, N., Sengupta, U., Jerez, C., Kidd, M., Gandhi, S., & Kaye, R. (2024). C9orf72 Associated Dipeptide Protein Repeats Form A11-positive Oligomers in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. *Journal of Biological Chemistry*, 105628.
6. Candeias, E., Nunes-Costa, D., Pereira-Santos, A. R., Magalhães, J. D., Melo-Marques, I., Guedes, B., . . . Cardoso, S. M. (2024). Neurotoxicity induced by the microbial metabolite β -methylamino-L-alanine: pathways and mechanisms *Natural Molecules in Neuroprotection and Neurotoxicity* (pp. 747-778): Elsevier.
7. Carmona, A., Carboni, E., Gomes, L. C., Roudeau, S., Maass, F., Lenz, C., . . . Lingor, P. (2024). Metal dyshomeostasis in the substantia nigra of patients with Parkinson's disease or multiple sclerosis. *Journal of Neurochemistry*.
8. Chen, K., Gao, T., Liu, Y., Zhu, K., Wang, T., & Zeng, P. (2024). Identifying risk loci for FTD and shared genetic component with ALS: A large-scale multitrait association analysis. *Neurobiology of Aging*, 134, 28-39.
9. da Silva, I. S., Cardoso, A. R., & Sales, M. G. F. (2024). Electrochemical biosensor-based detection assays for early diagnosis of neurodegenerative disorders *Smart Diagnostics for Neurodegenerative Disorders* (pp. 155-177): Elsevier.
10. De Marchi, F., Venkatesan, S., Saraceno, M., Mazzini, L., & Grossini, E. (2024). Acetyl-L-carnitine and Amyotrophic Lateral Sclerosis: Current evidence and potential use. *CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders)*.
11. Gallo, S., Vignaroli, F., Contaldi, E., Vecchio, D., Corrado, L., D'Alfonso, S., . . . Magistrelli, L. (2024). Parkinson's disease and chronic inflammatory demyelinating polyneuropathy: Broadening the clinical spectrum of VCP mutations. *Parkinsonism & Related Disorders*, 118.
12. Goswami, A., & Carra, S. (2024). PML nuclear bodies: new players in familial amyotrophic lateral sclerosis-frontotemporal dementia? *Neural Regeneration Research*, 10.4103.
13. Hartopp, N., Markovinovic, A., Miller, C. C., & Gomez-Suaga, P. (2024). Insight into endoplasmic reticulum-mitochondria contacts in human amyotrophic lateral sclerosis. *Neural Regeneration Research*, 19(7), 1407-1408.
14. Huo, D., Liang, W., Wang, D., Liu, Q., Wang, H., Wang, Y., . . . Tan, X. (2024). Roflupram alleviates autophagy defects and reduces mutant hSOD1-induced motor neuron damage in cell and mouse models of amyotrophic lateral sclerosis. *Neuropharmacology*, 109812.
15. Iskusnykh, I. Y., Zakharova, A. A., Kryl'skii, E. D., & Popova, T. N. (2024). Aging, Neurodegenerative Disorders, and Cerebellum. *International Journal of Molecular Sciences*, 25(2), 1018.
16. Jeong, S. H., Cha, J., Yoo, H. S., Chung, S. J., Jung, J. H., Sohn, Y. H., & Lee, P. H. (2024). Different effect of hypo-and hypermetabolism on cognition in dementia with Lewy bodies: are they coupled or independent? *npj Parkinson's Disease*, 10(1), 4.
17. Jia, F., Zhang, B., Yu, W., Chen, Z., Xu, W., Zhao, W., & Wang, Z. (2024). Exploring the cuproptosis-related molecular clusters in the peripheral blood of patients with amyotrophic lateral sclerosis. *Computers in Biology and Medicine*, 168, 107776.
18. Klíčová, K., Mareš, J., Menšíková, K., Kaiserová, M., Friedecký, D., Kaňovský, P., . . . Matěj, R. (2024). Utilizing neurodegenerative markers for the diagnostic evaluation of amyotrophic lateral sclerosis. *European Journal of Medical Research*, 29(1), 1-9.
19. Kwon, Y., Kang, M., Jeon, Y.-M., Lee, S., Lee, H.-W., Park, J.-S., & Kim, H.-J. (2024). Identification and characterization of novel ERBB4 variant associated with sporadic amyotrophic lateral sclerosis (ALS). *Journal of the Neurological Sciences*, 122885.
20. Leonard, H., Jonson, C., Levine, K., Lake, J., Hertslet, L., Jones, L., . . . Terry, N. (2024). Assessing the lack of diversity in genetics research across neurodegenerative diseases: a systematic review of the GWAS Catalog and literature. *medRxiv*, 2024.2001. 2008.24301007.
21. Liu, S., Sun, X., Ren, Q., Chen, Y., Dai, T., Yang, Y., . . . Meng, X. (2024). Glymphatic dysfunction in patients with early-stage amyotrophic lateral sclerosis. *Brain*, 147(1), 100-108.

22. Mahin, A., Soman, S. P., Modi, P. K., Raju, R., Keshava Prasad, T. S., & Abhinand, C. S. (2024). Meta-analysis of the serum/plasma proteome identifies significant associations between COVID-19 and Alzheimer's/Parkinson's diseases. *Journal of NeuroVirology*, 1-14.
23. Manera, U., Matteoni, E., Canosa, A., Callegaro, S., Casale, F., Marchis, D., . . . Calvo, A. (2024). Mycotoxins and Amyotrophic Lateral Sclerosis: food exposure, nutritional implications and dietary solutions. *CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders)*.
24. Martinelli, I., Zucchi, E., Simonini, C., Gianferrari, G., Bedin, R., Biral, C., . . . Mandrioli, J. (2024). SerpinA1 levels in amyotrophic lateral sclerosis patients: An exploratory study. *European Journal of Neurology*, 31(1), e16054.
25. Morrow, C. B. (2024). Geriatric Psychiatry and the Future of Dementia Care: Diagnosing TDP-43 Neurodegenerative Disease. *The American Journal of Geriatric Psychiatry*, 32(1), 114-116.
26. Neubrand, V. E., Sepúlveda, M. R., Dias, C., Nylandsted, J., Gothié, J.-D. M., Kennedy, T. E., . . . Torii, T. (2024). 1421 A dysregulated calcium homeostasis as the earliest pathological sign in stem cell-derived Parkinson's disease neurons? *Neural Regeneration Research*, 19(7), 1393.
27. Payne, T., Burgess, T., Bradley, S., Roscoe, S., Sassani, M., Dunning, M. J., . . . Taylor, R. (2024). Multimodal assessment of mitochondrial function in Parkinson's disease. *Brain*, 147(1), 267-280.
28. Sofyantoro, F., Frediansyah, A., Putri, W. A., Adipuri, W., Ramadaningrum, F. N., & Sharma, R. (2024). 10 Herbal Medicines. *Nanoarchitectonics for Brain Drug Delivery*, 210.
29. Tsuji, K., Nakayama, Y., Taruya, J., & Ito, H. (2024). Persistence of Kii amyotrophic lateral sclerosis after the 2000s and its characteristic aging-related tau astroglipathy. *Journal of Neuropathology & Experimental Neurology*, nlad113.
30. Wang, H., Liu, Y.-T., Ren, Y.-L., Guo, X.-Y., & Wang, Y. (2024). Association of peripheral immune activation with amyotrophic lateral sclerosis and Parkinson's disease: A systematic review and meta-analysis. *Journal of Neuroimmunology*, 578290.
31. Wang, Y., Liu, L., Chen, H., Yang, Y., Mu, C., Ren, H., . . . Wang, G. (2024). Disrupted phase behavior of FUS underlies poly-PR-induced DNA damage in amyotrophic lateral sclerosis. *Human Molecular Genetics*, 33(1), 64-77.
32. Wu, F., Malek, A. M., Buchanich, J. M., Arena, V. C., Rager, J. R., Sharma, R. K., . . . Talbott, E. O. (2024). Exposure to ambient air toxicants and the risk of amyotrophic lateral sclerosis (ALS): A matched case control study. *Environmental Research*, 242, 117719.
33. Xiang, Y., Huang, X., Xu, Q., Liu, Z., Chen, Y., Sun, Q., . . . Yan, X. (2024). Estimating the sequence of biomarker changes in Parkinson's disease. *Parkinsonism & Related Disorders*, 118, 105939.
34. Xuan, X., Zheng, G., Zhu, W., Sun, Q., Zeng, Y., Du, J., & Huang, X. (2024). Alterations in regional homogeneity and functional connectivity in the cerebellum of patients with sporadic amyotrophic lateral sclerosis. *Behavioural Brain Research*, 458, 114749.
35. Young, A. L., Oxtoby, N. P., Garbarino, S., Fox, N. C., Barkhof, F., Schott, J. M., & Alexander, D. C. (2024). Data-driven modelling of neurodegenerative disease progression: thinking outside the black box. *Nature Reviews Neuroscience*, 1-20.
36. Yu, W., Yu, F., Li, M., Yang, F., Wang, H., Song, H., & Huang, X. (2024). Quantitative association between lead exposure and amyotrophic lateral sclerosis: a Bayesian network-based predictive study. *Environmental Health*, 23(1), 2.